With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Source: 
Endpoints
snippet: 

When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis right behind Biogen, which he sees as a frontrunner 18 months ahead.